RIKEN Program for Drug Discovery and Medical Technology Platforms
Pipeline
Visualizing Research and Development Progress
The Drug Discovery and Medical Technology Platforms aim to implement innovative drug discovery and medical technologies based on areas of disease with low levels of therapeutic satisfaction, orphan drugs and new concepts. With respect to the drug creation and medical technology platforms listed in the chart below, we are currently placing maximum priority on moving to the next stage, reviewing the stages on a monthly basis to identify issues, and promoting effective research and development. For the selection of drug discovery themes, we have established guidelines to evaluate the novelty and reliability of the mechanisms, geared toward surveys of the literature and dedicated databases as well as evaluation of binding sites.
（List of themes and projects can download here.
）
＜Projects＞
| Project Name | Project Leader |
seg. | Stage | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S0 | S1 | S2 | S3 | L1 | L2 | L3 | P0 | P1 | P2 | P3 | ||||
| Artificial Adjuvant Vector Cells | Shin-ichiro Fujii |
RM/ CT |
≫ | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | P1 | - | ||
| Cancer Treatment by NKT Cell | Hiroshi Ohno |
RM/ CT |
≫ | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | P1 | - | ||
| Cancer Treatment by NKT Cell | Haruhiko Koseki |
RM/ CT |
≫ | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | P0 | - | |||
| Next-Generation Implant | Takashi Tsuji |
RM/ CT |
≫ | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | P0 | - | |||
| Regenerative Medicine for Retinal Degenerative Disease | Michiko Mandai |
RM/ CT |
≫ | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | P0 | → | |||
| Regenerative Medicine for Hair Follicle | Takashi Tsuji |
RM/ CT |
≫ | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | P0 | - | |||
| Fiblodysplasia Ossificans Progressiva | Kohei Miyazono |
LM | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | P0 | - | |||
| Drug for Allergic Disease | Masato Kubo |
LM | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | L3 | - | ||||
| Epigenetic Target III | Hiroyuki Seimiya |
LM | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | L3 | - | ||||
| Regenerative Medicine for Retinal Degenerative Disease | Masayo Takahashi | RM/ CT |
E | X | I | T | → | |||||||
| Regenerative Medicine for Heart Failure | Akifumi Matsuyama | RM/ CT |
E | X | I | T | - | |||||||
| Leukemia Treatment Drug Targeting Stem Cell | Fumihiko Ishikawa | LM | E | X | I | T | → | |||||||
| Cancer Treatment by NKT Cell | Masaru Taniguchi | RM/ CT |
E | X | I | T | - | |||||||
| Antithrombotic Drug without Hemorrhagic Side-effects | Toshio Miyata | LM | E | X | I | T | - | |||||||
| Alzheimer Disease | Hachiro Sugimoto | LM | E | X | I | T | - | |||||||
*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy
＜Themes＞
| Cancer | ||||||||||||||
| Theme Name | Theme Leader | seg. | Stage | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S0 | S1 | S2 | S3 | L1 | L2 | L3 | P0 | P1 | P2 | P3 | ||||
| Epigenetic Target I | Takashi Umehara |
LM | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | L2 | - | ||||
| Novel DDS Carrier | Motoki Ueda |
DDS | ≫ | ≫ | ≫ | ≫ | ≫ | ≫ | L2 | - | ||||
| Epigenetic Target IV | Hiroyuki Aburatani |
LM | ≫ | ≫ | ≫ | S3 | - | |||||||
| Drug for Refractory Solid Cancer Targeting Stem Cell |
Kenkichi Masutomi |
LM | ≫ | ≫ | ≫ | S3 | - | |||||||
| Artificial Adjuvant Vector Cells | Shin-ichiro Fujii |
RM/ CM |
≫ | ≫ | ≫ | S3 | - | |||||||
| Epigenetic Target VI | Akihiro Ito |
LM | ≫ | ≫ | S2 | - | ||||||||
| Oncogene Target | Tohru Kataoka |
LM | ≫ | ≫ | S2 | - | ||||||||
| Epigenetic Target VII | Yusuke Furukawa |
LM | ≫ | ≫ | S2 | - | ||||||||
| Epigenetic Target VIII | Takehiko Kamijo |
LM | ≫ | S1 | - | |||||||||
| Antibody Drug for NK/T Cell Lymphoma | Yasuyuki Ishii |
AB | E | X | I | T | - | |||||||
| Drug for Brain Tumor by Photodynamic Therapy | Toshihisa Ishikawa | LM | E | X | I | T | - | |||||||
*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy
| Infection | ||||||||||||||
| Theme Name | Theme Leader | seg. | Stage | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S0 | S1 | S2 | S3 | L1 | L2 | L3 | P0 | P1 | P2 | P3 | ||||
| Antifungal Drug | Minoru Yoshida |
LM | ≫ | ≫ | ≫ | ≫ | L1 | - | ||||||
| Drug for Chagas Disease | Akiko Tanaka |
LM | ≫ | ≫ | ≫ | S3 | - | |||||||
| Antibody Drug for Hepatitis B | Daiki Miki |
AB | ≫ | ≫ | ≫ | S3 | - | |||||||
| Antimalarial Drug | Nobumoto Watanabe |
LM | ≫ | ≫ | S2 | - | ||||||||
| Drug for Hepatitis B | Kenji Ogawa |
LM | ≫ | S1 | - | |||||||||
| Drug for RNA viruses | Kenji Ogawa |
LM | ≫ | S1 | - | |||||||||
*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy
| CNS Disease | ||||||||||||||
| Theme Name | Theme Leader | seg. | Stage | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S0 | S1 | S2 | S3 | L1 | L2 | L3 | P0 | P1 | P2 | P3 | ||||
| Gene therapy for Retinitis Pigmentosa |
Akishi Onishi |
GT | ≫ | ≫ | ≫ | S3 | - | |||||||
| Alzheimer Disease | Naoyuki Taniguchi |
LM | ≫ | S1 | - | |||||||||
| Drug for Bipolar Disorder | Tadafumi Kato |
LM | ≫ | S1 | - | |||||||||
| Drug for Dementia | Teijiro Aso |
LM | ≫ | S1 | - | |||||||||
*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy
| Congenital Disease | ||||||||||||||
| Theme Name | Theme Leader | seg. | Stage | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S0 | S1 | S2 | S3 | L1 | L2 | L3 | P0 | P1 | P2 | P3 | ||||
| Drug for Hemoglobinopathy | Akihiro Ito |
LM | ≫ | ≫ | ≫ | ≫ | L1 | - | ||||||
| Drug for Genetic Disorder | Tadashi Suzuki |
LM | ≫ | S1 | - | |||||||||
*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy
| Gastrointestinal Disease | ||||||||||||||
| Theme Name | Theme Leader | seg. | Stage | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S0 | S1 | S2 | S3 | L1 | L2 | L3 | P0 | P1 | P2 | P3 | ||||
| Antibody Drug for IBD | Takashi Saito |
AB | ≫ | ≫ | ≫ | S3 | - | |||||||
| Drug for IBD | Mikako Shirouzu |
LM | ≫ | ≫ | S2 | - | ||||||||
*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy
| Basic Technology | ||||||||||||||
| Theme Name | Theme Leader | seg. | Stage | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S0 | S1 | S2 | S3 | L1 | L2 | L3 | P0 | P1 | P2 | P3 | ||||
| Cardiomyopathy | Hidetoshi Masumoto |
BT | ≫ | S1 | - | |||||||||
*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy
| Drug Discovery Support Network | ||||||||||||||
| Theme Name | Theme Leader | seg. | Stage | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taget Valid. | Screening | Lead Opt. | Pre-clinical | clinical | ||||||||||
| Anticancer Drug / Antiviral Drug | Kazutoshi Mori |
LM | ≫ | ≫ | - | |||||||||
*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy
＜Closed Themes＞
| Theme Name | Theme Leader | seg. | Stage | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S0 | S1 | S2 | S3 | L1 | L2 | L3 | P0 | P1 | P2 | P3 | ||||
| Antibody Drug for cancer Targeting ErbB | Shigeyuki Yokoyama | AB | ≫ | ≫ | ≫ | S3 | - | |||||||
| Antcancer Drug Targeting p53 Restriction Protein | Akiko Tanaka | LM | ≫ | ≫ | S2 | - | ||||||||
| Antiviral Drug for Influenza | Yoko Aida | LM | ≫ | ≫ | S2 | - | ||||||||
| Osteoarthritis | Shiro Ikegawa | AB | ≫ | S1 | - | |||||||||
| Epigenetic Target | Minoru Yoshida | LM | ≫ | S1 | - | |||||||||
| Drug for Hepatitis C | Takehisa Matsumoto | LM | ≫ | S1 | - | |||||||||
| Drug for pulmonary Hypertension | Yukihito Ishizaka | LM | ≫ | S1 | - | |||||||||
| New Stabilized Nucleic Acid Drug | Ishiro Hirao / Hidefumi Mukai |
NA | ≫ | S1 | - | |||||||||
| Alzheimer Disease | Takaomi Saido | LM | ≫ | S1 | - | |||||||||
| Antibody Drug for Viral Liver Cirrhosis | Soichi Kojima | AB | ≫ | ≫ | ≫ | S3 | - | |||||||
| Drug for HIV | Yoko Aida | LM | ≫ | S1 | - | |||||||||
| Mucosal Vaccine Delivery System | Hiroshi Ohno | LM | ≫ | S1 | - | |||||||||
| Antibody Drug for CD8 T-Cell Related Disease | Tsuneyasu Kaisho | AB | ≫ | ≫ | ≫ | S3 | - | |||||||
| Drug for Autoimmune Disease | Akari Suzuki | LM | ≫ | S1 | - | |||||||||
| Antibody Drug for Hepatic Disease | Soichi Kojima | AB | ≫ | ≫ | S2 | - | ||||||||
| Hay Fever Drug / Prophylaxis Drug | Masaru Taniguchi | V | - | |||||||||||
| Drug for Cancer Metastasis | Masatoshi Takeichi | LM | ≫ | S1 | - | |||||||||
| Huntington Disease | Masatoshi Hagiwara | LM | ≫ | S1 | - | |||||||||
| Rheumatoid Arthritis | Makoto Kawatani | LM | ≫ | ≫ | ≫ | S3 | - | |||||||
| Drug for Sleep Disorder | Yukinari Ito | LM | ≫ | ≫ | S2 | - | ||||||||
| PET Imaging of Apoptosis Cells | Yasuko Matsumoto | Diag. | ≫ | ≫ | ≫ | ≫ | L1 | - | ||||||
| Drug for AML | Issay Kitabayashi | AB | ≫ | ≫ | ≫ | ≫ | ≫ | L2 | - | |||||
| Epigenetic Target II | Akihiro Ito | LM | ≫ | ≫ | ≫ | ≫ | L1 | - | ||||||
| Epigenetic Target V | Tetsu Akiyama | LM | ≫ | ≫ | S2 | - | ||||||||
| Antibody Drug for Glioma | Toru Kondo | AB | ≫ | ≫ | ≫ | ≫ | ≫ | L2 | - | |||||
| Antibody Drug for Leukemia | Fumihiko Ishikawa | AB | ≫ | ≫ | ≫ | S3 | - | |||||||
*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy
The Challenges of Rare and Incurable Diseases
This program has embarked on research and development of rare and incurable diseases in areas where pharmaceutical companies find it difficult to engage. We are currently targeting Fibrodysplasia Ossificans Progressiva (FOP). This disease is said to afflict one in 2 million people and starts in childhood with all the muscles and surrounding membranes, tendons and ligaments in the body gradually hardening and turning to bone (heterotopic ossification). As a result, the internal structures are crushed by ossification preventing muscle stretching, walking or eating, leading to death when it becomes impossible to breathe. Patients are no longer able to move their bodies by age 30 and prolonging life until age 40 is rare. At present, the disease is considered incurable. This program expects to develop inhibitors for newly identified target proteins and we are also advancing studies of "enhanced applications" for the inhibitor to interface with pharmaceutical companies.
Promoting Alliances of Drug Discovery and Medical Technologies Themes
-Looking for Corporate Partners!-
The program is looking for partners for the drug discovery and medical technology themes and projects mentioned above.
If you are interested in any of these themes, please see the Business Development Office Page.
